DK1404377T3 - Forbedrede chelatorkonjugater - Google Patents

Forbedrede chelatorkonjugater

Info

Publication number
DK1404377T3
DK1404377T3 DK02745600T DK02745600T DK1404377T3 DK 1404377 T3 DK1404377 T3 DK 1404377T3 DK 02745600 T DK02745600 T DK 02745600T DK 02745600 T DK02745600 T DK 02745600T DK 1404377 T3 DK1404377 T3 DK 1404377T3
Authority
DK
Denmark
Prior art keywords
chelator conjugates
improved
improved chelator
radiometal
conjugates
Prior art date
Application number
DK02745600T
Other languages
Danish (da)
English (en)
Inventor
Torgrim Engell
Colin Mill Archer
Harry John Wadsworth
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Application granted granted Critical
Publication of DK1404377T3 publication Critical patent/DK1404377T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32Oximes
    • C07C251/34Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/36Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0002General or multifunctional contrast agents, e.g. chelated agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
DK02745600T 2001-07-10 2002-07-10 Forbedrede chelatorkonjugater DK1404377T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0116815.2A GB0116815D0 (en) 2001-07-10 2001-07-10 Improved chelator conjugates

Publications (1)

Publication Number Publication Date
DK1404377T3 true DK1404377T3 (da) 2006-01-30

Family

ID=9918227

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02745600T DK1404377T3 (da) 2001-07-10 2002-07-10 Forbedrede chelatorkonjugater

Country Status (21)

Country Link
US (2) US7597875B2 (ko)
EP (1) EP1404377B1 (ko)
JP (1) JP5015409B2 (ko)
KR (1) KR100892009B1 (ko)
CN (4) CN101538313A (ko)
AT (1) ATE304866T1 (ko)
AU (1) AU2002317317B2 (ko)
BR (1) BR0210965A (ko)
CA (1) CA2450690C (ko)
DE (1) DE60206272T2 (ko)
DK (1) DK1404377T3 (ko)
ES (1) ES2250671T3 (ko)
GB (1) GB0116815D0 (ko)
HK (1) HK1064585A1 (ko)
HU (1) HU228850B1 (ko)
IL (1) IL159388A0 (ko)
MX (1) MXPA04000210A (ko)
NO (1) NO334093B1 (ko)
RU (1) RU2298012C2 (ko)
WO (1) WO2003006070A2 (ko)
ZA (1) ZA200400143B (ko)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2433657A1 (en) * 2001-01-05 2002-07-11 Duke University Contrast enhancement agent for magnetic resonance imaging
RU2303042C2 (ru) * 2001-07-10 2007-07-20 Джи-И Хелткер АС Соединения на основе пептидов для направленной доставки к рецепторам интегринов
NO20030115D0 (no) 2003-01-09 2003-01-09 Amersham Health As Kontrastmiddel
GB0416062D0 (en) 2004-07-19 2004-08-18 Amersham Plc Improved N4 chelator conjugates
WO2005044313A2 (en) * 2003-11-06 2005-05-19 Amersham Health As Conjugates of angiotensin ii and an imaging moiety
US7431914B2 (en) 2003-11-24 2008-10-07 Ge Healthcare As Contrast agent
EP1729823B1 (en) * 2004-03-04 2009-11-04 GE Healthcare AS Conjugates of angiotensin peptidic analogues and chelating agents for diagnosis and therapy
KR20070091609A (ko) * 2004-11-22 2007-09-11 지이 헬스케어 에이에스 세포외 기질을 표적화하기 위한 조영제
WO2006131803A2 (en) * 2005-06-08 2006-12-14 Ge Healthcare Limited Method for the use of [11c] carbon monoxide in labeling synthesis of 11c-labelled esters and acids by sensitized photo-induced free radical carbonylation
GB0515974D0 (en) * 2005-08-03 2005-09-07 Ge Healthcare Ltd Compounds and imaging methods
ES2357861T3 (es) 2006-02-15 2011-05-03 Ge Healthcare As Agentes de contraste.
US7943117B2 (en) * 2006-06-08 2011-05-17 Atomic Energy Council—Institute of Nuclear Research Method for testing radiochemical purity of Tc-99m-TRODAT-1
EP2101826B1 (en) * 2006-12-11 2010-06-23 GE Healthcare AS Radiolabelled peptide based compounds and uses thereof
CN102300866B (zh) * 2008-12-02 2015-08-26 墨尔本大学 作为放射性药物的含氮大环共轭物
GB0922014D0 (en) 2009-12-17 2010-02-03 Ge Healthcare Ltd Novel integrin binders
CN107362376A (zh) * 2010-07-27 2017-11-21 通用电气健康护理有限公司 放射性药物组合物
GB201103696D0 (en) * 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
GB201110767D0 (en) 2011-06-24 2011-08-10 Ge Healthcare Ltd Infection imaging
US20130195756A1 (en) * 2012-01-31 2013-08-01 General Electric Company 99mTc IMAGING AGENTS AND METHODS OF USE
WO2014126902A1 (en) * 2013-02-15 2014-08-21 Thomas Jefferson University Kit for tumor imaging
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
PT3131585T (pt) 2014-03-19 2020-10-23 Univ Zuerich Agentes quelantes bifuncionais multidentados para complexação de radionuclídeos em diagnóstico e terapia
WO2019217571A1 (en) * 2018-05-08 2019-11-14 University Of Miami Materials and methods for the delivery of therapeutic nucleic acids to tissues
WO2019222454A1 (en) 2018-05-16 2019-11-21 Emory University Styrylbenzothiazole derivatives and uses in imaging
CN111548275A (zh) * 2020-05-27 2020-08-18 龙曦宁(上海)医药科技有限公司 一种2-(氨基甲基)-n1,n1-二甲基丙烷-1,3-二胺三盐酸盐的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1588978A (en) * 1977-07-19 1981-05-07 Ici Ltd Coating processes
DE3930674A1 (de) * 1989-09-11 1991-03-21 Diagnostikforschung Inst Bifunktionelle chelatbildner zur komplexierung von tc- und re-isotopen, verfahren zu ihrer herstellung und darstellung von konjugaten daraus sowie deren verwendung in diagnostik und therapie
US5808091A (en) * 1991-10-29 1998-09-15 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia localizing moiety
CA2168652A1 (en) * 1993-08-04 1995-02-16 Colin Mill Archer Radiometal complexes that localise in hypoxic tissue
WO1995019187A1 (en) * 1994-01-12 1995-07-20 Amersham International Plc Biological targeting agents
ES2114735T3 (es) * 1994-01-12 1998-06-01 Bracco Int Bv Ligandos y complejos metalicos de los mismos.
ATE384075T1 (de) 1998-05-15 2008-02-15 Ge Healthcare Ltd Markierte glutamin- und lysinanaloge
US6783711B2 (en) * 2000-05-23 2004-08-31 Ge Osmonics, Inc. Process for preparing a sulfonamide polymer matrix
WO2002072718A1 (fr) * 2001-03-08 2002-09-19 Matsushita Electric Industrial Co., Ltd. Encre d'impression a jet d'encre, procede de production de l'encre, cartouche d'encre et dispositif d'impression comportant cette encre

Also Published As

Publication number Publication date
CN101607913B (zh) 2012-07-04
EP1404377A2 (en) 2004-04-07
WO2003006070A3 (en) 2003-08-21
WO2003006070A2 (en) 2003-01-23
NO20035597L (no) 2004-03-03
IL159388A0 (en) 2004-06-01
BR0210965A (pt) 2004-06-08
HK1064585A1 (en) 2005-02-04
ES2250671T3 (es) 2006-04-16
AU2002317317B2 (en) 2005-11-17
CN1527727A (zh) 2004-09-08
CA2450690A1 (en) 2003-01-23
DE60206272D1 (de) 2005-10-27
HU228850B1 (en) 2013-06-28
KR20040017287A (ko) 2004-02-26
KR100892009B1 (ko) 2009-04-07
CN101538313A (zh) 2009-09-23
ZA200400143B (en) 2004-12-29
US20100040542A1 (en) 2010-02-18
MXPA04000210A (es) 2004-07-23
JP5015409B2 (ja) 2012-08-29
US8852550B2 (en) 2014-10-07
HUP0401265A2 (hu) 2004-09-28
GB0116815D0 (en) 2001-08-29
JP2005500325A (ja) 2005-01-06
HUP0401265A3 (en) 2005-11-28
DE60206272T2 (de) 2006-07-13
NO334093B1 (no) 2013-12-09
US20040258619A1 (en) 2004-12-23
EP1404377B1 (en) 2005-09-21
ATE304866T1 (de) 2005-10-15
CN101607913A (zh) 2009-12-23
RU2298012C2 (ru) 2007-04-27
CA2450690C (en) 2009-03-24
RU2003137592A (ru) 2005-05-20
US7597875B2 (en) 2009-10-06
NO20035597D0 (no) 2003-12-16
CN101537190A (zh) 2009-09-23
CN100509061C (zh) 2009-07-08

Similar Documents

Publication Publication Date Title
DK1404377T3 (da) Forbedrede chelatorkonjugater
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
DK1791571T3 (da) Radiofluorinerede peptider
DE60230890D1 (de) Indolizine als kinaseproteinhemmer
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
MXPA05009682A (es) Metodos de radiofluorinacion de vectores biologicamente activos.
ECSP034600A (es) Compuestos de lactama
CL2013002895A1 (es) Compuestos derivados de 7,8-dihidro-5h-pteridin-6-ona, utiles como intermediarios en la sintesis de compuestos derivados de pteridinona (divisional de la solicitud 3123-2005).
ATE289640T1 (de) Amidofunktionelle aminopolydiorganosiloxane
MA30042B1 (fr) Composes calcilytiques
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
DE60210598D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
DE60322562D1 (de) Konjugate von tc komplexen und zielgerichtete einheiten und ihre verwendung in nmr-diagnostik
TR199901017A2 (xx) B�cek ilac� terkibi.
DE60213084D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
ID27733A (id) Metoksiminofenilasetamida
DE60330629D1 (de) Ether von 2,2,4-Trimethylpentane-1,3-Diolen als Duftstoff
ITMI20030827A1 (it) Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
NO20021429D0 (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
ES2183543T3 (es) Derivado de tiocolchicosida, su preparacion y su aplicacion en terapeutica.
ITMI20030851A1 (it) Kit per impedire di russare, nonche' procedimento per la sua realizzazione.
UA115859C2 (uk) Розчинний поліпептид, який зв'язує активін а, та композиція, що його містить